{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:57:53Z","timestamp":1789624673302,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"vor","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["474745\/2013-9"],"award-info":[{"award-number":["474745\/2013-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88881.132603\/2016-01"],"award-info":[{"award-number":["88881.132603\/2016-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.antiviral.2019.104621","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T01:53:06Z","timestamp":1571363586000},"page":"104621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons"],"prefix":"10.1016","volume":"172","author":[{"given":"Daiane J.","family":"Viegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri G.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104621_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijpam.2018.05.004","article-title":"Approach to recurrent herpes simplex encephalitis in children","volume":"5","author":"Alsweed","year":"2018","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104621_bib2","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1021\/acschembio.6b00074","article-title":"Conformational adaption may explain the slow dissociation kinetics of roniciclib (BAY 1000394), a type i cdk inhibitor with kinetic selectivity for Cdk2 and Cdk9","volume":"11","author":"Ayaz","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2019.104621_bib3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","article-title":"Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human Cdk2 complexed with roscovitine","volume":"243","author":"Azevedo","year":"1997","journal-title":"Eur. J. Biochem."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104621_bib4","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1021\/acs.jmedchem.6b00389","article-title":"Discovery of (s)-1--4(1-(4-Chloro-3-Fluorophenyl)-2-Hydroxyethyl)-Py(2-((1-Methyl-1 H -Pyrazol-5-Yl)Amino)Pyrimidin-4-Yl)Ridin-2-o(1 H )Ne , (GDC-0994)an extracellular signal-regulated kinase 1\/2 (ERK1\/2) inhibitor in early clinical development","volume":"59","author":"Blake","year":"2016","journal-title":"J. Med. Chem."},{"issue":"3\u20134","key":"10.1016\/j.antiviral.2019.104621_bib5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbagrm.2009.12.001","article-title":"Epigenetic regulation of latent HSV-1 gene expression","volume":"1799","author":"Bloom","year":"2010","journal-title":"Biochim. Biophys. Acta BBA - Gene Regul. Mech."},{"issue":"10","key":"10.1016\/j.antiviral.2019.104621_bib6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of cdk drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104621_bib7","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1073\/pnas.77.4.2265","article-title":"Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1","volume":"77","author":"Coen","year":"1980","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.antiviral.2019.104621_bib8","author":"Cyclacel Pharmaceutical"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104621_bib9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/JVI.76.3.1077-1088.2002","article-title":"The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 Icp0","volume":"76","author":"Davido","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104621_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02210-18","article-title":"Lund human mesencephalic (luhmes) neuronal cell line supports hsv-1 latency in vitro","author":"Edwards","year":"2019","journal-title":"J. Virol."},{"issue":"S1","key":"10.1016\/j.antiviral.2019.104621_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jmv.1890410503","article-title":"Acyclovir: discovery, mechanism of action, and selectivity","volume":"41","author":"Elion","year":"1993","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104621_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.survophthal.2012.01.005","article-title":"Herpes simplex epithelial and stromal keratitis: an epidemiologic update","volume":"57","author":"Farooq","year":"2012","journal-title":"Surv. Ophthalmol."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104621_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","article-title":"Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104621_bib14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1747-0285.2007.00571.x","article-title":"Signposts of docking and scoring in drug design","volume":"70","author":"Gani","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"issue":"15","key":"10.1016\/j.antiviral.2019.104621_bib15","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"Swiss-model and the Swiss-pdb viewer: an environment for comparative protein modeling","volume":"18","author":"Guex","year":"1997","journal-title":"Electrophoresis"},{"issue":"S1","key":"10.1016\/j.antiviral.2019.104621_bib16","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1002\/elps.200900140","article-title":"Automated comparative protein structure modeling with SWISS-model and Swiss-PdbViewer: a historical perspective","volume":"30","author":"Guex","year":"2009","journal-title":"Electrophoresis"},{"issue":"4","key":"10.1016\/j.antiviral.2019.104621_bib17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/ci200617d","article-title":"Ligand-based virtual screening approach using a new scoring function","volume":"52","author":"Hamza","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2019.104621_bib18","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ejmech.2016.12.023","article-title":"Explicit treatment of active-site waters enhances quantum mechanical\/implicit solvent scoring: inhibition of CDK2 by new pyrazolo[1,5- a ]pyrimidines","volume":"126","author":"Hylsov\u00e1","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104621_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijos.2016.3","article-title":"New strategies against drug resistance to herpes simplex virus","volume":"8","author":"Jiang","year":"2016","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.antiviral.2019.104621_bib20","first-page":"85","article-title":"Neurological disorders associated with human alphaherpesviruses","volume":"vol. 1045","author":"Kawada","year":"2018"},{"issue":"19\u201320","key":"10.1016\/j.antiviral.2019.104621_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.drudis.2012.05.007","article-title":"Drug discovery in pharmaceutical industry: productivity challenges and trends","volume":"17","author":"Khanna","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"W1","key":"10.1016\/j.antiviral.2019.104621_bib22","doi-asserted-by":"crossref","first-page":"W409","DOI":"10.1093\/nar\/gks378","article-title":"ZINCPharmer: pharmacophore search of the ZINC database","volume":"40","author":"Koes","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104621_bib23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1021\/jm0302997","article-title":"Evaluation of docking performance: comparative data on docking algorithms","volume":"47","author":"Kontoyianni","year":"2004","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.antiviral.2019.104621_bib24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase ii study of the national cancer institute of Canada clinical trials group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104621_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cmdc.200900314","article-title":"Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors","volume":"5","author":"Kr\u00fcger","year":"2010","journal-title":"ChemMedChem"},{"issue":"20","key":"10.1016\/j.antiviral.2019.104621_bib26","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1021\/jm060999m","article-title":"Prediction of Protein\u2212ligand interactions. Docking and scoring: successes and gaps","volume":"49","author":"Leach","year":"2006","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.antiviral.2019.104621_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6446(01)01712-3","article-title":"Screening for human ADME\/Tox drug properties in drug discovery","volume":"6","author":"Li","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2019.104621_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2019.104621_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.virol.2015.02.040","article-title":"The role of PI3K\/akt in human herpesvirus infection: from the bench to the bedside","volume":"479\u2013480","author":"Liu","year":"2015","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.antiviral.2019.104621_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.antiviral.2019.104621_bib31","first-page":"365","article-title":"Molecular docking","volume":"vol. 443","author":"Morris","year":"2008"},{"issue":"16","key":"10.1016\/j.antiviral.2019.104621_bib32","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.antiviral.2019.104621_bib33","unstructured":"PROMEGA. CellTiter-Glo\u00ae One Solution Assay. Technical Bulletin TB370."},{"key":"10.1016\/j.antiviral.2019.104621_bib34","series-title":"Reproduction","first-page":"229","article-title":"The replication of herpesviruses","author":"Roizman","year":"1974"},{"issue":"21","key":"10.1016\/j.antiviral.2019.104621_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01161-17","article-title":"The UL21 tegument protein of herpes simplex virus 1 is differentially required for the syncytial phenotype","volume":"91","author":"Sarfo","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104621_bib36","first-page":"103","article-title":"The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections","volume":"5","author":"Schang","year":"2003","journal-title":"Cell Cycle Res"},{"issue":"7","key":"10.1016\/j.antiviral.2019.104621_bib37","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1128\/JVI.72.7.5626-5637.1998","article-title":"Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription","volume":"72","author":"Schang","year":"1998","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.antiviral.2019.104621_bib38","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1128\/JVI.76.15.7724-7735.2002","article-title":"Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear Cdk2 and Cdk4","volume":"76","author":"Schang","year":"2002","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104621_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/095632020601700601","article-title":"Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs","volume":"17","author":"Schang","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104621_bib40","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1471-4159.2011.07255.x","article-title":"Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line: LUHMES as widely applicable neuronal model System","volume":"119","author":"Scholz","year":"2011","journal-title":"J. Neurochem."},{"issue":"23","key":"10.1016\/j.antiviral.2019.104621_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00958-17","article-title":"Differentiated human sh-sy5y cells provide a reductionist model of herpes simplex virus 1 neurotropism","volume":"91","author":"Shipley","year":"2017","journal-title":"J. Virol."},{"issue":"7019","key":"10.1016\/j.antiviral.2019.104621_bib42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nature03197","article-title":"Virtual screening of chemical libraries","volume":"432","author":"Shoichet","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.104621_bib43","series-title":"Introduction to Theoretical Organic Chemistry and Molecular Modeling","author":"Smith","year":"1996"},{"issue":"2","key":"10.1016\/j.antiviral.2019.104621_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2000.18.2.371","article-title":"Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a university of chicago phase ii consortium study","volume":"18","author":"Stadler","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"W1","key":"10.1016\/j.antiviral.2019.104621_bib45","doi-asserted-by":"crossref","first-page":"W442","DOI":"10.1093\/nar\/gkw287","article-title":"Pharmit: interactive exploration of chemical space","volume":"44","author":"Sunseri","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.104621_bib46","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","author":"Trott","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104621_bib47","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1086\/342966","article-title":"Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 Years' experience with acyclovir","volume":"186","author":"Tyring","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104621_bib48","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104621_bib49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0968-0004(03)00088-4","article-title":"The herpes simplex virus VP16-induced complex: the makings of a regulatory switch","volume":"28","author":"Wysocka","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.antiviral.2019.104621_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neulet.2016.05.059","article-title":"The effect of cyclin-dependent kinases inhibitor treatment on experimental herpes simplex encephalitis mice","volume":"627","author":"Zhou","year":"2016","journal-title":"Neurosci. Lett."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219303833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219303833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:11:39Z","timestamp":1777497099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219303833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":50,"alternative-id":["S0166354219303833"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104621","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104621"}}